Shares surged 23.1% reflecting investor enthusiasm driven by stronger-than-expected volume growth in Decipher tests, advancing clinical catalysts, and improving profitability metrics.

• Decipher test volume rose 24% year-over-year to approximately 28,000 tests in Q1, driven by expanded provider adoption and higher orders per physician.
• Growth was particularly strong in high-risk prostate cancer categories, with nearly 30% volume increase in advanced disease segments.
• Multiple late-stage clinical trials (including GUIDANCE and ENZAMET) advancing, supporting Decipher’s potential as a treatment decision biomarker.
• Adjusted EBITDA margin exceeded expectations, reflecting ongoing operational efficiency improvements.
• Upcoming product launches (Prosigna LDT and TrueMRD) represent important growth levers to extend the platform and address new clinical settings.